Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy of Orlistat in reducing liver fat content by magnetic resonance imaging in obese patients with non-alcoholic steatohepatitis

Trial Profile

Efficacy of Orlistat in reducing liver fat content by magnetic resonance imaging in obese patients with non-alcoholic steatohepatitis

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Orlistat (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Dec 2017 New trial record
    • 01 Nov 2017 Interim analysis (n=51) presented at the 25th United European Gastroenterology Week.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top